Downgrade Alert for Monsanto (MON)

Print Share

Jan 09, 2013 (SmarTrend(R) Upgrades/Downgrades via COMTEX) -- Monsanto (NYSE:MON) was downgraded from Buy to Hold at Miller Tabak today. The stock closed yesterday at $98.50 on volume of 7.4 million shares, above average daily volume of 2.3 million. Potential upside of 6.0% exists for Monsanto, based on a current level of $98.50 and analysts' average consensus price target of $104.38. Monsanto shares have support at the 50-day moving average (MA) of $90.07 and additional support at the 200-day MA of $84.43.

Monsanto Company provides agricultural products for farmers. The Company's business segments are seeds and genomics. Monsanto produces a wide range of seeds and develops biotechnology traits that assist farmers in controlling insects andweeds as well as provides other seed companies with genetic material and biotechnology traits for their seed brands.

Over the past year, Monsanto has traded in a range of $69.70 to $99.99 and closed yesterday at $98.50, 41% above that low. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.6% while the 200-day MA has risen 0.3%.

SmarTrend recommended that subscribers consider buying shares of Monsanto on November 20th, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $88.71. Since that recommendation, shares of Monsanto have risen 11.0%. We continue to monitor MON for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Write to Chip Brian at


SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at:

Copyright, Comtex News Network, Inc. 2013

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.